Compare fureasu Co., Ltd. with Similar Stocks
Dashboard
1
With a growth in Operating Profit of 638.08%, the company declared Very Positive results in Jun 25
- The company has declared positive results in Jan 70 after 5 consecutive negative quarters
- NET PROFIT(HY) Higher at JPY -121.01 MM
- DEBTORS TURNOVER RATIO(HY) Highest at 5.47%
- NET SALES(Q) Highest at JPY 2,393.73 MM
2
With ROCE of -3.45%, it has a risky valuation with a 1.05 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,142 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.26
4.17%
1.10
Revenue and Profits:
Net Sales:
2,199 Million
(Quarterly Results - Sep 2025)
Net Profit:
344 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.14%
0%
13.14%
6 Months
-31.49%
0%
-31.49%
1 Year
-30.74%
0%
-30.74%
2 Years
-10.01%
0%
-10.01%
3 Years
-4.66%
0%
-4.66%
4 Years
-23.69%
0%
-23.69%
5 Years
3.94%
0%
3.94%
fureasu Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.86%
EBIT Growth (5y)
-207.20%
EBIT to Interest (avg)
5.93
Debt to EBITDA (avg)
3.76
Net Debt to Equity (avg)
0.97
Sales to Capital Employed (avg)
1.79
Tax Ratio
72.52%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.49%
ROE (avg)
3.35%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.10
EV to EBIT
-30.52
EV to EBITDA
23.83
EV to Capital Employed
1.05
EV to Sales
0.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.45%
ROE (Latest)
-15.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
2,199.40
2,393.70
-8.12%
Operating Profit (PBDIT) excl Other Income
151.60
62.90
141.02%
Interest
34.90
43.00
-18.84%
Exceptional Items
20.00
0.00
Consolidate Net Profit
344.30
-70.80
586.30%
Operating Profit Margin (Excl OI)
41.10%
-5.20%
4.63%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -8.12% vs 18.18% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 586.30% vs -37.74% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
7,582.60
5,710.00
32.80%
Operating Profit (PBDIT) excl Other Income
134.60
267.40
-49.66%
Interest
102.30
38.90
162.98%
Exceptional Items
-1.10
-4.80
77.08%
Consolidate Net Profit
-244.50
58.30
-519.38%
Operating Profit Margin (Excl OI)
-13.90%
19.40%
-3.33%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 32.80% vs 24.56% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -519.38% vs 84.49% in Mar 2024
About fureasu Co., Ltd. 
fureasu Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






